Abstract: Silk coated and/or infused performance materials, apparel, and methods of preparing the same are disclosed herein. In some embodiments, silk performance apparel includes textiles, fabrics, consumer products, and other materials that are coated with aqueous solutions of pure silk fibroin-based protein fragments having low, medium, and/or high molecular weight in various ratios.

Abstract: Silk coated and/or infused performance materials, apparel, and methods of preparing the same are disclosed herein. In some embodiments, silk performance apparel includes textiles, fabrics, consumer products, and other materials that are coated with aqueous solutions of pure silk fibroin-based protein fragments having low, medium, and/or high molecular weight in various ratios.

Abstract: Silk processed, coated, repaired, and/or infused leather or leather articles, and methods of preparing the same are disclosed herein. In some embodiments, the invention relates to silk-coated leather apparel and products for use in home and automotive applications, such as leather coated with pure silk fibroin-based proteins or protein fragments thereof. In some embodiments, the invention relates to silk and silk protein fragments compositions, and methods of making and using thereof, for processing leather, for example coating leather, and/or repairing, hiding, or masking defects on or within leather, and/or as a mixing agent, additive, or replacement for leather processing chemicals.

Abstract: Silk coated and/or infused performance materials, apparel, and methods of preparing the same are disclosed herein. In some embodiments, silk performance apparel includes textiles, fabrics, consumer products, and other materials that are coated with aqueous solutions of pure silk fibroin-based protein fragments having low, medium, and/or high molecular weight in various ratios.

Abstract: The present invention relates to novel analogues of insulin-like growth factor-1 (IGF-1), pharmaceutical compositions containing said analogues, and the use of said analogues for treatment of IGF-1-receptor mediated conditions, such as short stature, diabetes therapy, neurodegenerative disease treatment, and cartilage repair. More particularly, the present invention relates to novel analogues of IGF-1 having an amino acid substitution at position 59, e.g., (Asn59)hIGF-1(1-70)-OH (SEQ ID NO:1), and other substitution(s) as defined herein.

Abstract: The present invention relates to novel analogues of insulin-like growth factor-1 (IGF-1), pharmaceutical compositions containing said analogues, and the use of said analogues for treatment of IGF-1-receptor mediated conditions, such as short stature, diabetes therapy, neurodegenerative disease treatment, and cartilage repair. More particularly, the present invention relates to novel analogues of IGF-1 having an amino acid substitution at position 59, e.g., (Asn59)hIGF-1(1-70)-OH (SEQ ID NO:1), and other substitution(s) as defined herein.